ResearcherUniversity of MichiganActive in the last 2 years
Nguyen H. Tran
Matched on ORCID iD 0000-0002-6104-6489; OpenAlex author ID A5041256351. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 41
2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 7
- Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. Co-author DOI 10.21037/jgo-2025-100↗
- Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Co-author DOI 10.2147/ceg.s390655↗
- Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment bur… First author DOI 10.1007/s00262-023-03397-4↗
- FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
- Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. Co-author DOI 10.1001/jamanetworkopen.2021.34458↗
- The role of microbiome in pancreatic cancer. Co-author DOI 10.1007/s10555-021-09982-2↗
- Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resec… Co-author DOI 10.1016/j.ijrobp.2019.08.057↗
Closest collaborators
The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitesh J. Borad · 2 shared papers, 2024–2025 · strength 0.49
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655↗
- Paper Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a p… DOI 10.21037/jgo-2025-100↗
- Hani M. Babiker · 2 shared papers, 2024–2025 · strength 0.49
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655↗
- Paper Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a p… DOI 10.21037/jgo-2025-100↗
- Umair Majeed · 2 shared papers, 2024–2025 · strength 0.49
- Paper Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Cli… DOI 10.2147/ceg.s390655↗
- Paper Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a p… DOI 10.21037/jgo-2025-100↗
- Tanios Bekaii‐Saab · 2 shared papers, 2021 · strength 0.42
- Aminah Jatoi · 1 shared paper, 2023 · strength 0.26
- Michael Harrison Storandt · 1 shared paper, 2023 · strength 0.26
- Robin John Lester Imperial · 1 shared paper, 2024 · strength 0.26
- Osama M. Mosalem · 1 shared paper, 2024 · strength 0.26
- Wen Wee Ma · 2 shared papers, 2021–2022 · strength 0.26
- Robert R. McWilliams · 2 shared papers, 2021–2022 · strength 0.26
- Douaa Albelal · 1 shared paper, 2025 · strength 0.24
- Himil J Mahadevia · 1 shared paper, 2025 · strength 0.24
- Ahmed Elhariri · 1 shared paper, 2025 · strength 0.24
- Michael S. Rutenberg · 1 shared paper, 2025 · strength 0.24
- Nicholas Chia · 1 shared paper, 2021 · strength 0.14
- Jing Li · 1 shared paper, 2021 · strength 0.14
- Thorvardur Ragnar Halfdanarson · 1 shared paper, 2022 · strength 0.12
- Amro M. Abdelrahman · 1 shared paper, 2022 · strength 0.12
- Jennifer A. Yonkus · 1 shared paper, 2022 · strength 0.12
- Christopher Leigh Hallemeier · 1 shared paper, 2022 · strength 0.12
- Sean Patrick Cleary · 1 shared paper, 2022 · strength 0.12
- Jennifer L. Leiting · 1 shared paper, 2022 · strength 0.12
- Travis Edward Grotz · 1 shared paper, 2022 · strength 0.12
- Rondell Patrell Graham · 1 shared paper, 2022 · strength 0.12
- Roberto Alva‐Ruiz · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.